These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 26077912

  • 1. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

  • 2. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, Anders R, Karagkounis G, Choti MA, Pawlik TM.
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [Abstract] [Full Text] [Related]

  • 3. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Hashimoto M, Kokudo N.
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [Abstract] [Full Text] [Related]

  • 4. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI, Hyer JM, Bagante F, Guglielmi A, Ruzzenente A, Alexandrescu S, Poultsides G, Sasaki K, Aucejo F, Pawlik TM.
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [Abstract] [Full Text] [Related]

  • 5. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM.
    Cancer; 2016 Sep 01; 122(17):2698-707. PubMed ID: 27244540
    [Abstract] [Full Text] [Related]

  • 6. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.
    JAMA Surg; 2018 Jul 18; 153(7):e180996. PubMed ID: 29799910
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis.
    Moro A, Mehta R, Tsilimigras DI, Sahara K, Paredes AZ, Bagante F, Guglielmi A, Alexandrescu S, Poultsides GA, Sasaki K, Aucejo FN, Pawlik TM.
    Surgery; 2020 Sep 18; 168(3):497-503. PubMed ID: 32675031
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K, Margonis GA, Wilson A, Kim Y, Buettner S, Andreatos N, Gani F, Amini N, Spolverato G, Pawlik TM.
    Ann Surg Oncol; 2016 Oct 18; 23(11):3736-3743. PubMed ID: 27352204
    [Abstract] [Full Text] [Related]

  • 9. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
    Margonis GA, Kim Y, Sasaki K, Samaha M, Buettner S, Amini N, Pawlik TM.
    J Surg Oncol; 2016 Sep 18; 114(3):361-7. PubMed ID: 27264476
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, Pawlik TM.
    Surg Oncol; 2018 Jun 18; 27(2):280-288. PubMed ID: 29937183
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S, Kemeny NE, Boucher TM, Gönen M, Cercek A, Kingham TP, Balachandran V, Allen P, DeMatteo R, Drebin J, Jarnagin W, D'Angelica M.
    Ann Surg; 2020 Aug 18; 272(2):352-356. PubMed ID: 32675549
    [Abstract] [Full Text] [Related]

  • 12. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
    Margonis GA, Buettner S, Andreatos N, Sasaki K, Ijzermans JNM, van Vugt JLA, Pawlik TM, Choti MA, Cameron JL, He J, Wolfgang CL, Weiss MJ.
    Ann Surg; 2017 Oct 18; 266(4):641-649. PubMed ID: 28657938
    [Abstract] [Full Text] [Related]

  • 13. KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
    Zhang Q, Peng J, Ye M, Weng W, Tan C, Ni S, Huang D, Sheng W, Wang L.
    Ann Surg Oncol; 2020 Apr 18; 27(4):1164-1173. PubMed ID: 31720935
    [Abstract] [Full Text] [Related]

  • 14. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
    Andreatos N, Ronnekleiv-Kelly S, Margonis GA, Sasaki K, Gani F, Amini N, Wilson A, Pawlik TM.
    Surg Oncol; 2016 Sep 18; 25(3):332-8. PubMed ID: 27566041
    [Abstract] [Full Text] [Related]

  • 15. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
    Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C.
    Ann Surg Oncol; 2018 Aug 18; 25(8):2457-2466. PubMed ID: 29786130
    [Abstract] [Full Text] [Related]

  • 16. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM.
    Ann Surg; 2013 Oct 18; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [Abstract] [Full Text] [Related]

  • 17. Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.
    Margonis GA, Sasaki K, Kim Y, Samaha M, Buettner S, Amini N, Antoniou E, Pawlik TM.
    J Gastrointest Surg; 2016 Nov 18; 20(11):1821-1829. PubMed ID: 27384430
    [Abstract] [Full Text] [Related]

  • 18. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A.
    Crit Rev Oncol Hematol; 2016 Mar 18; 99():150-7. PubMed ID: 26775732
    [Abstract] [Full Text] [Related]

  • 19. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F, Magni E, Amatu A, Mauri G, Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G, Nichelatti M, Sartore-Bianchi A, Siena S.
    Clin Colorectal Cancer; 2017 Sep 18; 16(3):e153-e163. PubMed ID: 28216246
    [Abstract] [Full Text] [Related]

  • 20. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.
    Procopio F, Viganò L, Cimino M, Donadon M, Del Fabbro D, Torzilli G.
    Eur J Surg Oncol; 2020 May 18; 46(5):818-824. PubMed ID: 31839435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.